Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
9.65 million shs
Average Volume
848,888 shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

MedPharm appoints Bill Humphries as new CEO
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Alcami Announces CEO Transition
See More Headlines

PHAS Stock Analysis - Frequently Asked Questions

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to the consensus estimate of $2.67 million.

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Oncobiologics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
11/10/2021
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAS
CIK
1169245
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.07 million
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%
Return on Equity
N/A
Return on Assets
-174.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.47

Sales & Book Value

Annual Sales
$818 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.93) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
49,858,000
Free Float
44,922,000
Market Cap
$3.50 million
Optionable
Not Optionable
Beta
2.57
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:PHAS) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners